company background image
9966 logo

Alphamab Oncology SEHK:9966 Stock Report

Last Price

HK$4.27

Market Cap

HK$4.1b

7D

-10.3%

1Y

-74.0%

Updated

17 Apr, 2024

Data

Company Financials +

9966 Stock Overview

Alphamab Oncology, a clinical stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of oncology biologics.

9966 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Alphamab Oncology Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Alphamab Oncology
Historical stock prices
Current Share PriceHK$4.27
52 Week HighHK$16.70
52 Week LowHK$3.81
Beta0.37
1 Month Change-16.93%
3 Month Change-16.27%
1 Year Change-73.96%
3 Year Change-58.78%
5 Year Changen/a
Change since IPO-68.37%

Recent News & Updates

Recent updates

Optimistic Investors Push Alphamab Oncology (HKG:9966) Shares Up 27% But Growth Is Lacking

Mar 13
Optimistic Investors Push Alphamab Oncology (HKG:9966) Shares Up 27% But Growth Is Lacking

Subdued Growth No Barrier To Alphamab Oncology's (HKG:9966) Price

Jan 17
Subdued Growth No Barrier To Alphamab Oncology's (HKG:9966) Price

Slammed 40% Alphamab Oncology (HKG:9966) Screens Well Here But There Might Be A Catch

May 21
Slammed 40% Alphamab Oncology (HKG:9966) Screens Well Here But There Might Be A Catch

Newsflash: Alphamab Oncology (HKG:9966) Analysts Have Been Trimming Their Revenue Forecasts

Mar 01
Newsflash: Alphamab Oncology (HKG:9966) Analysts Have Been Trimming Their Revenue Forecasts

Is Alphamab Oncology (HKG:9966) Using Debt Sensibly?

Oct 04
Is Alphamab Oncology (HKG:9966) Using Debt Sensibly?

Is Alphamab Oncology (HKG:9966) A Risky Investment?

May 21
Is Alphamab Oncology (HKG:9966) A Risky Investment?

Rock star Growth Puts Alphamab Oncology (HKG:9966) In A Position To Use Debt

Oct 05
Rock star Growth Puts Alphamab Oncology (HKG:9966) In A Position To Use Debt

Is Alphamab Oncology (HKG:9966) Using Too Much Debt?

May 05
Is Alphamab Oncology (HKG:9966) Using Too Much Debt?

How Many Alphamab Oncology (HKG:9966) Shares Have Insiders Sold, In The Last Year?

Feb 09
How Many Alphamab Oncology (HKG:9966) Shares Have Insiders Sold, In The Last Year?

Should Alphamab Oncology (HKG:9966) Be Disappointed With Their 19% Profit?

Dec 30
Should Alphamab Oncology (HKG:9966) Be Disappointed With Their 19% Profit?

What Percentage Of Alphamab Oncology (HKG:9966) Shares Do Insiders Own?

Nov 25
What Percentage Of Alphamab Oncology (HKG:9966) Shares Do Insiders Own?

Shareholder Returns

9966HK BiotechsHK Market
7D-10.3%-6.1%-2.8%
1Y-74.0%-46.6%-15.0%

Return vs Industry: 9966 underperformed the Hong Kong Biotechs industry which returned -47.1% over the past year.

Return vs Market: 9966 underperformed the Hong Kong Market which returned -16.4% over the past year.

Price Volatility

Is 9966's price volatile compared to industry and market?
9966 volatility
9966 Average Weekly Movement10.5%
Biotechs Industry Average Movement9.5%
Market Average Movement7.4%
10% most volatile stocks in HK Market14.8%
10% least volatile stocks in HK Market3.8%

Stable Share Price: 9966's share price has been volatile over the past 3 months.

Volatility Over Time: 9966's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2008435Ting Xuwww.alphamabonc.com

Alphamab Oncology, a clinical stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of oncology biologics. Its product pipeline includes KN046, a bispecific monoclonal antibody (BsAb) immune checkpoint inhibitor, which is in Phase III clinical trials that targets clinically-validated immune checkpoints, including programmed death ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4); and KN026, a next generation anti-human epidermal growth factor receptor 2 (HER2) BsAb that is in Phase II clinical trials for neoadjuvant treatment of HER2-positive breast cancer and I/II clinical trial treatment of heavily pre-treated breast cancers, as well as Phase II clinical trial for HER2-positive solid tumors. The company’s product pipeline also comprises KN019, a CTLA-4-based immunosuppressant fusion protein, which is in Phase II clinical trial for auto-immune diseases and oncology treatment-induced immune disorders; and KN035, an injectable PD-L1 inhibitor that is in phase III clinical trials for advanced solid tumors with deficient mismatch repair/microsatellite instability-high solid tumors, and is in Phase III clinical trials for biliary tract cancer.

Alphamab Oncology Fundamentals Summary

How do Alphamab Oncology's earnings and revenue compare to its market cap?
9966 fundamental statistics
Market capHK$4.12b
Earnings (TTM)-HK$227.85m
Revenue (TTM)HK$236.71m

17.4x

P/S Ratio

-18.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
9966 income statement (TTM)
RevenueCN¥218.77m
Cost of RevenueCN¥55.24m
Gross ProfitCN¥163.54m
Other ExpensesCN¥374.13m
Earnings-CN¥210.59m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.22
Gross Margin74.75%
Net Profit Margin-96.26%
Debt/Equity Ratio15.0%

How did 9966 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.